Table 1.
Patient characteristics of METH-PAH patients involved in WES
| METH-PAH Cohort (n = 18) | |
|---|---|
| Age, yr | 47.8 ± 6.7 |
| Sex, men/women (%) | 7/11 (62%) |
| BMI, kg/m2 | 29.5 ± 3.8 |
| NYHA symptom class, n (%) | |
| I | 3 (16.7) |
| II | 6 (33.3) |
| III | 8 (44.4) |
| IV | 1 (5.6) |
| 6MWD, m | 486 ± 145 |
| Therapies, n (%) | |
| Prostacyclin | 12 (66.7) |
| ERA | 12 (66.7) |
| PDE-I | 15 (83.3) |
| CCB | 2 (11.1) |
| Hemodynamics | |
| mRA, mmHg | 10.3 ± 6.3 |
| mPAP, mmHg | 51.8 ± 15.8 |
| PCWP, mmHg | 11.4 ± 4.5 |
| CO, l/min | 4.2 ± 1.0 |
| PVR, WU | 10.7 ± 6.0 |
Values represent means ± SD; METH, methamphetamine; PAH, pulmonary arterial hypertension; WES, whole exome sequencing; BMI, body mass index; NYHA, New York Heart Association; 6MWD, 6-min walk distance; ERA, endothelin-1 receptor antagonist; PDE-I , phosphodiesterase inhibitor; CCB, calcium channel blocker; mRA, mean right atrial pressure; mPAP, mean pulmonary artery pressures; PCWP, pulmonary capillary wedge pressure; CO, cardiac output; PVR, pulmonary vascular resistance; WU wood units.